We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.
- Authors
Henein, Sandra; Swanstrom, Jesica; Byers, Anthony M.; Moser, Janice M.; Shaik, S. Farzana; Bonaparte, Matthew; Jackson, Nicholas; Guy, Bruno; Baric, Ralph; de Silva, Aravinda M.
- Abstract
Sanofi Pasteur has developed a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) that is currently approved for use in several countries. In clinical trials, CYD-TDV was efficacious at reducing laboratory-confirmed cases of dengue disease. Efficacy varied by dengue virus (DENV) serotype and prevaccination dengue immune status. We compared the properties of antibodies in naive and DENV-exposed individuals who received CYD-TDV. We depleted specific populations of DENV-reactive antibodies from immune serum samples to estimate the contribution of serotype-cross-reactive and type-specific antibodies to neutralization. Subjects with no preexisting immunity to DENV developed neutralizing antibodies to all 4 serotypes of DENV. Further analysis demonstrated that DENV4 was mainly neutralized by type-specific antibodies whereas DENV1, DENV2, and DENV3 were mainly neutralized by serotype cross-reactive antibodies. When subjects with preexisting immunity to DENV were vaccinated, they developed higher levels of neutralizing antibodies than naive subjects who were vaccinated. In preimmune subjects, CYD-TDV boosted cross-reactive neutralizing antibodies while maintaining type-specific neutralizing antibodies acquired before vaccination. Our results demonstrate that the quality of neutralizing antibodies induced by CYD-TDV varies depending on DENV serotype and previous immune status. We discuss the implications of these results for understanding vaccine efficacy.
- Subjects
CELL lines; CLINICAL trials; COMPARATIVE studies; DENGUE; FLAVIVIRUSES; IMMUNOGLOBULINS; RESEARCH methodology; MEDICAL cooperation; RESEARCH; RESEARCH funding; VACCINES; VIRAL antibodies; VIRAL vaccines; EVALUATION research; PREVENTION
- Publication
Journal of Infectious Diseases, 2017, Vol 215, Issue 3, p351
- ISSN
0022-1899
- Publication type
journal article
- DOI
10.1093/infdis/jiw576